Telix Pharmaceuticals files AGM materials for investors
Telix Pharmaceuticals Limited submitted a Form 6-K as a foreign private issuer, forwarding materials from its Annual General Meeting held in May 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
6-K
Rhea-AI Filing Summary
Telix Pharmaceuticals Limited submitted a Form 6-K as a foreign private issuer, forwarding materials from its Annual General Meeting held in May 2026. The filing makes available the Chairman and CEO addresses, an AGM presentation, and the results of the AGM as exhibits for U.S. investors.
Key Terms
Form 6-K, foreign private issuer, Annual General Meeting, Australian Securities Exchange
4 terms
Form 6-K regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.
foreign private issuer regulatory
"FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER"
A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.
Annual General Meeting financial
"Telix Annual General Meeting Chairman and CEO Addresses"
Australian Securities Exchange financial
"filed three announcements with the Australian Securities Exchange"
Australian Securities Exchange is Australia’s main marketplace where stocks, bonds, ETFs and other tradable financial instruments are bought and sold. Think of it as a large, regulated marketplace that shows current prices, matches buyers and sellers, and enforces rules to keep trading fair and orderly—information and liquidity from the exchange directly affect how easy it is to trade an investment and how its market price is determined.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Telix Pharmaceuticals (TLX) report in this Form 6-K?
Telix Pharmaceuticals reports that it has furnished three Australian Securities Exchange announcements related to its Annual General Meeting, including addresses, a presentation, and meeting results, as exhibits to this Form 6-K for U.S. investors.
Which AGM documents did Telix Pharmaceuticals (TLX) attach to the Form 6-K?
Telix attached three documents: AGM Chairman and CEO addresses, an AGM presentation, and the results of the Annual General Meeting, labeled as Exhibits 99.1, 99.2, and 99.3, respectively, to give U.S. investors access to those materials.
When were Telix Pharmaceuticals’ (TLX) AGM materials filed with the ASX?
The AGM-related announcements were filed with the Australian Securities Exchange on May 21, 2026, in Melbourne, Australia, and the same materials were then furnished to U.S. investors via this Form 6-K filing.
What is the purpose of Telix Pharmaceuticals (TLX) using Form 6-K?
Form 6-K allows Telix, as a foreign private issuer, to furnish important information released in its home market, such as AGM announcements, to U.S. investors so they receive the same key disclosures contemporaneously.
Who signed the Telix Pharmaceuticals (TLX) Form 6-K filing?
The Form 6-K was signed on behalf of Telix Pharmaceuticals Limited by Christian Krautkramer, the company’s Group General Counsel, confirming the company’s authorization of the submitted AGM-related exhibits.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2026
Commission File Number: 001-42128
Telix Pharmaceuticals Limited
(Translation of registrant’s name into English)
55 Flemington Road
North Melbourne, Victoria 3051, Australia
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
INFORMATION CONTAINED IN THIS FORM 6-K REPORT
On May 21, 2026 (Melbourne, Australia), Telix Pharmaceuticals Limited filed three announcements with the Australian Securities Exchange, titled (i) “Telix Annual General Meeting Chairman and CEO Addresses,” (ii) “Telix Annual General Meeting Presentation,” and (iii) “Results of Annual General Meeting,” copies of which are attached to this Form 6-K as Exhibits 99.1, 99.2, and 99.3, respectively.
|
99.1
|
ASX Announcement – AGM Addresses
|
|
99.2
|
ASX Announcement – AGM Presentation
|
| 99.3 | ASX Announcement – AGM Results |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
Telix Pharmaceuticals Limited
|
|
|
|
|
|
|
Date: May 21, 2026
|
By:
|
/s/ Christian Krautkramer
|
|
|
|
Name: Christian Krautkramer
|
|
|
|
Title: Group General Counsel
|
